Hope is on the horizon for needle-phobic patients as Griffith University researchers have created a new influenza vaccine ...

On September 20, 2024, the U.S. Food and Drug Administration (FDA) approved the first influenza (flu) vaccine for at‑home use. The vaccine, ...

The Global Needle Free Injectors Market is projected to grow from USD 1,478.9 Million in 2024 to USD 2,980.9 Million by 2033, ...

On a basic level, companies able to offer an alternative form of vaccine delivery to traditional options can set themselves apart from competitors. Needle phobia is a well-known problem ...

Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology is currently being evaluated in a phase 1 clinical study of the first needle-free COVID-19 vaccine, having demonstrated ...

One such alternative is needle-free vaccines and studies have focused on the immune response few have addressed the welfare implications. This study aims to compare the impact of intradermal ...

Partners’ data continues to support PharmaJet’s Tropis ® and Stratis ® Needle-free Delivery Systems as optimal methods for ...

World Vaccine Congress – Europe 2024 presentation, Improving Performance of Vaccines with Needle-free Technology will highlight the results of recent studies using needle-free delivery across ...

PharmaJet ®, a company that strives to improve the performance and outcomes of injectables with its enabling needle-free ...

Hope is on the horizon for needle-phobic patients as Griffith University researchers have created a new influenza vaccine ...